Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay.
Chronic hepatitis B virus (HBV) infection often develop into cirrhosis, and both are major risk factors of hepatocellular carcinoma. However, effective approaches for the monitoring of HBV-related disease progress are still in need. Increased iron storage has an important role in HBV-related diseases. Hepcidin is a key regulator of iron homeostasis whose expression changes are often indicative of abnormal iron metabolism. There are few reports of hepcidin levels in patients with HBV infections, and the available results are inconsistent. In this study, using a recently validated nanopore silica film based method, we measured serum hepcidin levels in 46 HBV-related patients and 20 healthy controls. Patients were divided into three groups: chronic hepatitis B without cirrhosis; HBV-related cirrhosis; and HBV-related cirrhosis with hepatocellular carcinoma. Compared to healthy controls, the mean serum hepcidin level was significantly higher in CHB patients without cirrhosis, and in those with hepatocellular carcinoma, but not in those with cirrhosis. Iron-loading, viral infection and liver dysfunction are determined to be the major regulators of hepcidin in these patients. These observations suggest correlations between serum hepcidin and progression of chronic HBV infection, and may shed a new light on the development of biomarkers for HBV-related disease surveillance.
CAS Key Laboratory for Biomedical Effects of Nanomaterials &Nanosafety, Beijing Key Laboratory of Ambient Particles Health Effects and Prevention Techniques, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Jing
J
Wang
CAS Key Laboratory for Biomedical Effects of Nanomaterials &Nanosafety, Beijing Key Laboratory of Ambient Particles Health Effects and Prevention Techniques, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.|The First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China.
Ailian
A
Dong
CAS Key Laboratory for Biomedical Effects of Nanomaterials &Nanosafety, Beijing Key Laboratory of Ambient Particles Health Effects and Prevention Techniques, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Gang
G
Liu
Iron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, 4006 Australia.
Gregory J
GJ
Anderson
Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA.
Tony Y
TY
Hu
CAS Key Laboratory for Biomedical Effects of Nanomaterials &Nanosafety, Beijing Key Laboratory of Ambient Particles Health Effects and Prevention Techniques, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Jian
J
Shi
The First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China.
Yulin
Y
Hu
CAS Key Laboratory for Biomedical Effects of Nanomaterials &Nanosafety, Beijing Key Laboratory of Ambient Particles Health Effects and Prevention Techniques, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Guangjun
G
Nie
D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000097:blood; D018450:Disease Progression; D005260:Female; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic / Q000097:blood*; D064451:Hepcidins / Q000097:blood*; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D058608:Nanopores
C578702:HAMP protein, human; D064451:Hepcidins; D008567:Membranes, Artificial
J Cancer Res Clin Oncol. 2009 Oct;135(10):1413-20
19387685
PLoS One. 2012;7(6):e39276
22723983
Metallomics. 2014 Sep;6(9):1583-90
24874645
J Clin Gastroenterol. 2005 Jan;39(1):71-4
15599216
Gastroenterology. 2007 Jan;132(1):294-300
17241879
Blood. 2003 Aug 1;102(3):783-8
12663437
Annu Rev Med. 2011;62:347-60
20887198
BMC Nephrol. 2012 Jul 07;13:56
22768976
Gastroenterology. 1992 Jun;102(6):2108-13
1587431
Nanomedicine. 2015 May;11(4):871-8
25659646
Infect Dis Clin North Am. 2009 Jun;23(2):315-30
19393912
J Viral Hepat. 2010 Nov;17(11):800-6
20002304
Dig Dis Sci. 2010 Dec;55(12):3548-51
20238243
Nanomedicine. 2014 Jul;10(5):879-88
24566273
Biomarkers. 2008 Aug;13(5):478-85
18979640
Am J Clin Nutr. 2009 Feb;89(2):475-6
19088153
J Biol Chem. 2001 Mar 16;276(11):7811-9
11113132
Hepatology. 2013 May;57(5):2072-7
23150189
BMC Cancer. 2008 Jun 09;8:167
18541040
Cell. 2010 Jul 9;142(1):24-38
20603012
Science. 2012 Nov 9;338(6108):768-72
23139325
Blood. 2011 Oct 13;118(15):4129-39
21873546
PLoS One. 2013 Jun 11;8(6):e65551
23776499
J Gastroenterol Hepatol. 2008 Apr;23(4):512-20
18397482
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e68-74
22429447
Br J Nutr. 2007 Mar;97(3):544-9
17313717
Acta Med Scand. 1967 Jul;182(1):83-92
6028955
World J Gastroenterol. 1999 Feb;5(1):38-40
11819382
Biochim Biophys Acta. 2002 Oct 2;1603(1):31-46
12242109
Eur J Gastroenterol Hepatol. 2010 Apr;22(4):461-5
19940783
J Hepatol. 2001 Jan;34(1):108-13
11211885
Cell. 2004 Apr 30;117(3):285-97
15109490
Nat Rev Microbiol. 2008 Jul;6(7):541-52
18552864
Blood Cells Mol Dis. 2002 Nov-Dec;29(3):327-35
12547223
Ann Clin Lab Sci. 2013 Spring;43(2):126-34
23694786
Clin Chem. 2010 Oct;56(10):1570-9
20739637
World J Gastroenterol. 2010 Apr 14;16(14 ):1747-52
20380007
J Hepatol. 2008 Nov;49(5):702-10
18620776
Ann N Y Acad Sci. 2009 Feb;1155:206-21
19250206
ISRN Hematol. 2012;2012:567491
22461996
J Hepatol. 2015 Apr;62(4):977-9
25463544
Hepatol Res. 2006 Dec;36(4):288-93
16979376
Hepatology. 2005 Nov;42(5):1208-36
16250051
J Hepatol. 2009 Nov;51(5):845-52
19729219
J Viral Hepat. 2008 Jul;15(7):498-507
18331251
Surgery. 1992 Feb;111(2):201-9
1736391
Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G199-203
16407589